Sunday, April 23, 2006
17:30 - 19:00

HPV Viral persistence and clinical utility of HPV genotyping

• Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia
  Prof. K.U. Petry
• AMPLICOR HPV and LINEAR ARRAY HPV Genotyping studies in South Africa and Haiti
  Thomas C. Wright, Jr., MD

Monday, April 24, 2006
11:30 - 13:00

The value of vaccines: extending the success to HPV
Free lunchbox provided

Chair: Pierre Van Damme
Co-chair: Hugues Bogaerts

11.30-11.50	Modern vaccines: science & innovation		Fred Zepp (G)
11.50-12.10	HPV vaccination strategies: mobilize all stakeholders		Pierre Van Damme (B)
12.10-12.30	GSK vaccines: innovative pipeline		Hugues Bogaerts (B)
12.30-12.50	The development of GSK’s prophylactic HPV vaccine		Cosette Wheeler (US)
12.50-13.00	Q&A

Monday, April 24, 2006
17:30 - 19:00

Widening the benefit: a Quadrivalent Human Papillomavirus vaccine and women’s health

Chair: Dr. C. Bergeron (France)

• The wider impact on Women’s Health – More than Invasive cervical cancer?
  Prof. N. Colombo (Italy)
• Human Papillomavirus and the pathogenesis of Cervical Cancer
  Prof. M. Stanley (UK)
• Management of Low Grade Cervical Dysplasia (CIN 1) – A Swedish perspective
  Dr. K. Elfgren (Sweden)
• A review of the Phase III Clinical Data for the Quadrivalent Human Papillomavirus Vaccine
  Dr. N. Muñoz (France)
• Closing remarks - Dr. C. Bergeron

Tuesday, April 25, 2006
11:30 - 12:30

Has molecular testing given us the most optimal screening method?

1. Evaluation of cervical cancer screeening methods with respect to test positivity and disease prevalence
   By Professor Jack Cuzick – 10 minutes
2. The difference between direct and indirect (biomarker) detection of oncogene expression in future screening of invasive cervical cancer
   By Professor John O’Leary – 10 minutes
3. Recent experiences related to the difference between transient/latent and transforming infection
   By Dr Antoinette Brink – 10 minutes
4. How important is it to detect only clinical relevant HPV infections in screening settings?
   By Dr Heather Cubie – 10 minutes
5. PreTect HPV-Proofer: the optimal screening kit?
   By Dr Hanne Skomedal and Dr Frank Karlsen – 10 minutes

Tuesday, April 25, 2006
11:30 - 12:30

“ThinPrep – Discover the Value of the Vial”

Complimentary Lunch boxes and wine available
Pre-register on-line

Chairman:  Dr Euphemia McGoogan

• ThinPrep: improved glandular disease detection
  Prof Raheela Ashfaq
• ThinPrep plus Imaging: increased HSIL sensitivity and productivity
  Dr Jonathan Weintraub
• ThinPrep: out of the vial testing and PreQuot
  Prof John O’Leary

Tuesday, April 25, 2006
11:30 - 12:30

Advocacy and Vaccination: The Voice of the Health Care Provider
(free lunchbox provided)

Tuesday, April 25, 2006
12:30 - 14:00

HPV Screening and Vaccines:   New Strategies for Prevention and Elimination of Cervical Cancer
(free lunchbox provided)

Tuesday, April 25, 2006
17: 30 - 19:00

The Application of Molecular Diagnostics Designed for Cervical Disease Detection:

Results from Expanded Studies using SurePath® with ProEx™ C and the future of the Molecular Pap Test

Douglas P. Clark, M.D.
Director of Cytopathology
Associate Professor of Pathology and Oncology
The Johns Hopkins Medical Institutions
Baltimore, MD

Christophe E. Depuydt, Ph. D.
Molecular Biologist
Laboratory for Clinical Pathology
(Labo RIATOL)
Antwerp, Belgium

Dorothy L. Rosenthal, MD, FIAC
Professor of Pathology, Oncology and Gynecology & Obstetrics
The Johns Hopkins Medical Institutions
Baltimore, MD

Tuesday, April 25, 2006
17: 30 - 19:00

Dr. Christopher CRUM, Harvard University

Tuesday, April 25, 2006
17:30 - 19:00

Meet the Experts
(Private Session)

Wednesday, April 26, 2006
10:00 - 11:30

From FUTURE to the future

Chair: Prof. K.U. Petry

• A review of the Phase III Clinical Data for the Quadrivalent Human Papillomavirus Vaccine
  Dr. N. Muñoz (France)
• Clinical efficacy in HPV positive women – Widening the Benefit
  Prof. D. Ferris (US)
• HPV type replacement in the post vaccination era?
  Prof. J. Dillner (Sweden)
• HPV vaccine implementation: Back to the FUTURE
  Prof. A. Finn (UK)
• Closing remarks
  Prof. KU Petry

Wednesday, April 26, 2006
11:30 - 13:00

Vaccinating women against Cervical Cancer: the role of the gynaecologist

Chair: Chris Meijer

Co-chair & Introduction: David Jenkins

11.30-11.50	Spectrum of HPV related burden of disease		Jennifer Smith (US)
11.50-12.10	Integration of vaccination & screening		Chris Meijer (NL)
12.10-12.30	Patient awareness of HPV & Cervical Cancer		Jane Wardle (UK)
12.30-12.50	The role of the gynaecologist in vaccinating women against Cervical Cancer		Joseph Monsonego (F)
12.50-13.00	Q&A

Wednesday, April 26, 2006
13:00 - 14:00

When does it make sense to add p16INK4a in cervical cytology and histology?
(free lunchbox provided)

1. The value of p16 INK4a as a prognostic marker of CIN1
   by J. Hariri ( Denmark)
2. p16 INK4a as a predictive marker of CIN in women with abnormal Pap smear
   by R. Dachez ( France)
3. Evaluation of p16 INK4a in a clinical setting
   by Dr. Schlederman